Consun Pharma

Consun Pharma, a pharmaceutical preparation manufacturer based in China (CN), has disclosed its greenhouse gas emissions for several years. In 2022, the company reported total emissions of approximately 72,057,200 kg CO2e, comprising approximately 53,214,680 kg CO2e in Scope 1 emissions and approximately 18,842,520 kg CO2e in Scope 2 emissions. For 2021, total emissions were approximately 71,151,211 kg CO2e, with Scope 1 at approximately 52,549,121 kg CO2e and Scope 2 at approximately 18,602,090 kg CO2e. In 2020, Consun Pharma's emissions totalled approximately 31,857,680 kg CO2e, with Scope 1 at approximately 16,418,910 kg CO2e and Scope 2 at approximately 15,438,760 kg CO2e. The company's emissions for 2019 were approximately 28,163,260 kg CO2e, consisting of approximately 15,470,130 kg CO2e in Scope 1 and approximately 12,693,130 kg CO2e in Scope 2. Prior to this, in 2017, total emissions were reported at approximately 21,049,000 kg CO2e, with Scope 1 emissions from stationary combustion amounting to approximately 12,397,000 kg CO2e and Scope 2 emissions from purchased electricity at approximately 7,978,000 kg CO2e.

It is important to note that Scope 3 emissions data have not been disclosed by Consun Pharma for the years reported.

While Consun Pharma's own reduction targets are not explicitly detailed in the provided information, its parent company, Asker, has established a commitment to reduce absolute Scope 1 and 2 emissions by at least 42% by 2030, using 2021 as the base year. This commitment is cascaded from Asker, which is the ultimate parent company through a corporate family relationship.